◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › G › GYRE

Gyre Therapeutics Inc. (GYRE) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-24

Gyre Therapeutics Inc. (GYRE) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 625 employees. Its market capitalization is roughly $471 million. In the fiscal year ended 2025-12-31, GYRE reported $117M in revenue and $5M in net income.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

Interactive charts & full statements → Open the GYRE valuation workbench →

GYRE Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$119M	$117M	$106M	$113M	$102M	$7M	$21M	—	$0M	$1M	$0M	$2M	$2M	$4M	$58M	$98M	$86M	$25M	$20M	$12M	$28M
Gross Profit	$113M	$111M	$102M	$109M	$97M	$0M	$12M	$0M	$0M	$1M	($10M)	($4M)	($3M)	($3M)	$58M	$95M	$84M	$24M	$19M	$11M	$27M
Gross Margin %	94.3%	95.3%	96.3%	95.9%	95.3%	-4.5%	56.3%	—	-2383.3%	83.0%	-2545.4%	-240.5%	-190.5%	-80.7%	100.0%	97.5%	97.7%	97.2%	96.3%	93.8%	98.3%
Operating Income (EBIT)	($17M)	$11M	$16M	($67M)	$9M	($84M)	($57M)	($57M)	($34M)	($22M)	($20M)	($14M)	($8M)	($47M)	($5M)	($10M)	$13M	($40M)	($28M)	($32M)	$0M
Operating Margin %	-14.0%	9.9%	15.3%	-59.3%	9.0%	-1141.0%	-273.9%	—	-563700.0%	-2143.6%	-5117.3%	-788.7%	-414.2%	-1301.1%	-8.4%	-10.0%	15.3%	-160.9%	-140.1%	-274.5%	-1.5%
Net Income	($17M)	$5M	$12M	($93M)	$2M	($88M)	($56M)	($55M)	($30M)	($22M)	($17M)	($15M)	($33M)	($47M)	($7M)	($9M)	$11M	($39M)	($26M)	($28M)	$2M
Net Margin %	-14.5%	4.3%	11.4%	-81.9%	2.2%	-1198.3%	-265.1%	—	-500916.7%	-2118.0%	-4246.9%	-843.5%	-1799.4%	-1287.0%	-12.1%	-8.7%	12.7%	-157.2%	-127.8%	-242.5%	7.6%
EBITDA	($14M)	$17M	$18M	$20M	$11M	($88M)	($56M)	($55M)	($34M)	($22M)	($20M)	($13M)	($7M)	($47M)	($3M)	($7M)	$15M	($38M)	($26M)	($31M)	$0M
Earnings Per Share (EPS)	$-0.18	$0.05	$0.12	$-1.41	$0.03	$-2.87	$-2.90	$-4.60	$-2.68	$-6.30	$-21.76	$-49.99	$-101.40	$-145.78	$-21.95	$-28.31	$37.96	$-161.39	$-109.24	$-149.47	$16.19
Shares Outstanding (M)	101M	103M	102M	66M	76M	31M	19M	12M	11M	3M	1M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GYRE Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$29M	$23M	$37M	$31M	$30M	$22M	$28M	$25M
Gross Profit	$27M	$21M	$35M	$29M	$29M	$21M	$27M	$25M
Gross Margin %	92.4%	94.5%	95.3%	94.7%	96.1%	96.0%	95.8%	96.2%
Operating Income (EBIT)	($14M)	($9M)	$0M	$7M	($2M)	$2M	$1M	$4M
Operating Margin %	-49.4%	-41.5%	0.3%	22.7%	-7.5%	10.3%	2.4%	16.6%
Net Income	($11M)	($9M)	($2M)	$4M	$1M	$3M	$0M	$1M
Net Margin %	-36.4%	-38.3%	-4.6%	11.8%	2.0%	12.2%	-0.4%	4.4%
EBITDA	($14M)	($9M)	$1M	$8M	($1M)	$5M	$1M	$4M
Earnings Per Share (EPS)	$-0.11	$-0.09	$-0.02	$0.04	$0.01	$0.03	$-0.00	$0.01
Shares Outstanding (M)	101M	91M	103M	103M	89M	102M	102M	103M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GYRE Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	($14M)	$1M	($4M)	$26M	$11M	($84M)	($55M)	($44M)	($29M)	($20M)	($18M)	($19M)	($34M)	($41M)	($64M)	($84M)	$138M	($24M)	($28M)	$25M	($10M)
Capital Expenditures (CapEx)	$2M	$1M	$3M	$9M	$5M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$3M	$0M	$2M	$5M	$1M
Free Cash Flow (FCF)	($17M)	$0M	($7M)	$17M	$6M	($85M)	($55M)	($44M)	($29M)	($20M)	($19M)	($19M)	($34M)	($41M)	($65M)	($85M)	$135M	($24M)	($30M)	$20M	($11M)
FCF Margin %	-14.1%	-0.1%	-6.4%	15.2%	5.5%	-1152.8%	-264.1%	—	-482150.0%	-1961.0%	-4746.9%	-1108.0%	-1902.2%	-1121.6%	-111.6%	-87.2%	157.5%	-97.6%	-150.9%	171.9%	-39.8%
Dividends Paid	—	—	—	—	$45M	$0M	—	—	—	$4M	—	—	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GYRE Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($17M)	$3M	($6M)	$5M	$2M	$0M	($3M)	$2M
Capital Expenditures (CapEx)	$1M	$0M	$0M	$1M	$0M	$1M	$1M	$1M
Free Cash Flow (FCF)	($18M)	$3M	($6M)	$4M	$2M	($1M)	($4M)	$1M
FCF Margin %	-61.9%	13.3%	-15.5%	13.1%	6.1%	-4.3%	-12.6%	3.9%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GYRE Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$199M	$166M	$125M	$117M	$85M	$56M	$95M	$99M	$125M	$40M	$38M	$70M	$112M	$146M	$190M	$258M	$263M	$319M	$99M	$99M	$81M
Cash & Cash Equivalents	$43M	$37M	$12M	$34M	$25M	$44M	$30M	$15M	$31M	$14M	$10M	$29M	$56M	$54M	$82M	$107M	$166M	$84M	$51M	$53M	$42M
Total Liabilities	$34M	$24M	$27M	$103M	$13M	$15M	$19M	$30M	$5M	$9M	$22M	$38M	$3M	$11M	$14M	$84M	$171M	$250M	$41M	$47M	$16M
Total Debt (Short + Long-Term)	$1M	$1M	$1M	$0M	$0M	$2M	$1M	$0M	$0M	$5M	$19M	$34M	$0M	$1M	$1M	$1M	$2M	$1M	$1M	$1M	$1M
Total Shareholders' Equity	$130M	$106M	$63M	($16M)	$43M	$41M	$76M	$68M	$120M	$31M	$16M	$31M	$109M	$135M	$176M	$174M	$92M	$69M	$57M	$52M	$65M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GYRE viewer.

Other Companies in BIOTECHNOLOGY

CBIO · Crescent Biopharma, Inc. — $485 million
CAPR · Capricor Therapeutics Inc — $479 million
CTMX · CytomX Therapeutics Inc — $475 million
MDXG · MiMedx Group Inc — $474 million
OCS · Oculis Holding AG Ordinary shares — $470 million
MNPR · Monopar Therapeutics Inc — $469 million
PHAT · Phathom Pharmaceuticals Inc — $467 million
ARVN · Arvinas Inc — $464 million

← GYM All “G” companies GYRO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.